Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJiaqi Li

Discussion

Loading...

Member takes

Overview

Prospective analysis shows sequential CD19/CD22 CAR-T therapy improves complete response rates in relapsed/refractory large B-cell lymphoma, suggesting better treatment strategies.

Key Points

  • Sequential therapy with CD19/CD22 CAR-T leads to improved overall response rates and complete responses in relapsed/refractory large B-cell lymphoma.
  • The study evaluated 50 patients, with 73.9% achieving complete response and a notable 100% overall response rate in the ASCT+CAR-T group.
  • This was a prospective single-arm analysis comparing sequential CAR-T therapy following ASCT with CAR-T monotherapy.
  • The results indicate that sequential CAR-T therapy may establish a new standard of care in relapsed/refractory large B-cell lymphoma.

Cite This Study

Jiaqi Li (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d58chttps://doi.org/10.1182/blood-2025-1933
View Full Paper
Ask AI
Bookmark
Share